Zacks Research Issues Optimistic Forecast for BMY Earnings

Bristol-Myers Squibb (NYSE:BMY) – Equities research analysts at Zacks Research increased their Q1 2027 earnings per share estimates for shares of Bristol-Myers Squibb in a research note issued on Wednesday, May 7th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will post earnings of $1.41 per share for the quarter, up from their previous forecast of $1.34. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $6.74 per share.

Other equities research analysts have also issued reports about the company. UBS Group cut their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a research report on Friday, April 11th. Wells Fargo & Company upped their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research note on Friday, February 7th. Piper Sandler began coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 price target for the company. Argus upgraded Bristol-Myers Squibb to a “hold” rating in a research note on Friday, April 25th. Finally, Jefferies Financial Group cut their price target on Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a report on Wednesday, April 23rd. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $58.00.

Bristol-Myers Squibb Stock Down 1.1%

Shares of Bristol-Myers Squibb stock opened at $46.38 on Monday. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The business’s fifty day moving average price is $54.54 and its two-hundred day moving average price is $56.23. The company has a market capitalization of $94.39 billion, a P/E ratio of -10.49, a PEG ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same quarter last year, the firm earned ($4.40) EPS. The business’s revenue was down 5.6% on a year-over-year basis.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were given a $0.62 dividend. The ex-dividend date was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a yield of 5.35%. Bristol-Myers Squibb’s payout ratio is 92.88%.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the company’s stock in a transaction that occurred on Friday, April 25th. The shares were acquired at an average price of $47.58 per share, with a total value of $202,215.00. Following the purchase, the executive vice president now owns 83,513 shares of the company’s stock, valued at $3,973,548.54. This represents a 5.36% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.09% of the stock is owned by corporate insiders.

Institutional Trading of Bristol-Myers Squibb

Hedge funds have recently added to or reduced their stakes in the business. Pinney & Scofield Inc. acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth $25,000. Park Square Financial Group LLC acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at about $26,000. Global Wealth Strategies & Associates raised its stake in shares of Bristol-Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 275 shares during the period. Transce3nd LLC acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at about $28,000. Finally, Fairway Wealth LLC acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at about $28,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.